433937-93-0

Basic information

• Product Name: AZD-0837
• Synonyms: AZD-0837;Atecegatran fexinitil/AZD0837;XSNMGLZVFNDDPW-ZWKOTPCHSA-N
• CAS NO: 433937-93-0
• Molecular Formula: C₂₂H₂₃ClF₂N₄O₅
• Molecular Weight: 496.89
• Mol File: 433937-93-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AZD-0837(CAS DataBase Reference)
• NIST Chemistry Reference: AZD-0837(433937-93-0)
• EPA Substance Registry System: AZD-0837(433937-93-0)

Safety Data

• Hazardous Substances Data: 433937-93-0(Hazardous Substances Data)

Usage

General Description

AZD-0837 is a selective and reversible inhibitor of the enzyme 11β-HSD1, which is involved in the conversion of inactive cortisone to active cortisol. This chemical has been studied for its potential use in the treatment of metabolic diseases such as type 2 diabetes and obesity, as well as for its anti-inflammatory effects. By blocking the activity of 11β-HSD1, AZD-0837 may help to reduce levels of cortisol in the body, which could in turn improve insulin sensitivity and decrease inflammation. However, further research is needed to fully understand the potential therapeutic benefits and safety profile of AZD-0837.

Upstream product

• 433938-79-5 Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-Aze-Pab(OMe,Teoc) 
• 433938-79-5 Ph(3-Cl)(5-OCHF₂)-(R)-CH(OH)C(O)-Aze-Pab(MeO, Teoc) 

Downstream Products

• 631916-92-2 C₂₂H₂₃ClF₂N₄O₅*HNO₃ 
• 631916-76-2 C₇H₈O₃S*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-13-0 C₄H₆O₅*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-17-4 C₆H₁₂O₇*C₂₂H₂₃ClF₂N₄O₅ 
• 631916-72-8 C₄H₄O₄*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-01-6 C₅H₉NO₄*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-09-4 C₄H₄O₄*C₂₂H₂₃ClF₂N₄O₅ 
• 631916-81-9 CH₄O₃S*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-15-2 C₄H₆O₅*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-11-8 C₆H₈O₇*C₂₂H₂₃ClF₂N₄O₅ 
• 631916-73-9 C₆H₁₃NO₃S*C₂₂H₂₃ClF₂N₄O₅ 
• 631917-06-1 C₇H₆O₃*C₂₂H₂₃ClF₂N₄O₅ 
• 631916-91-1 C₂H₆O₃S*C₂₂H₂₃ClF₂N₄O₅ 
• 631916-85-3 BrH*C₂₂H₂₃ClF₂N₄O₅ 

Relevant articles and documents

NEW CRYSTALLINE FORMS

There are provided crystalline forms of the compounds Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OMe) (Compound A) and Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OH) (Compound B), pharmaceutical compositions containing them, processes for obtaining them and their use in medical treatment.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.